[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413697":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":153,"collaborators":21,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":21,"enrollmentInfo":164,"targetDuration":21,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":44,"whyStopped":21,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Institut Cancerologie de l'Ouest","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Extended ductal carcinoma in situ with mastectomy indication","EXPERIMENTAL","Patients receive 6 months of tamoxifen or anastrozole in a neoadjuvant situation.\n\nTamoxifen and Anastrozole will be delivered in their original packaging at J0 and M3 :\n\n* Tamoxifen: box of tablets dosed at 20 mg\n* Anastrozole: box of tablets 1 mg. Tamoxifen will be initiated in premenopausal patients orally at a standard dose of 20mg\u002Fday as a single dose for 6 months.\n\nAnastrozole will be administered orally to postmenopausal patients at the standard dose of 1mg\u002Fday in a single dose for 6 months.",[13,14],"Drug: Tamoxifen 20 mg","Drug: Anastrozole 1Mg Tab",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Tamoxifen 20 mg","Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Anastrozole 1Mg Tab","Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.",[9],[27],{"name":28,"affiliation":29,"role":30},"Victoire BRILLAUD-MEFLAH, MD","Institut de Cancérologie de l'Ouest","PRINCIPAL_INVESTIGATOR",[32,37],{"name":28,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","0240679818","+33","Victoire.brillaud-meflah@ico.unicancer.fr",{"name":38,"role":33,"phone":39,"phoneExt":35,"email":40},"Emilie DEBEAUPUIS","0240679844","emilie.debeaupuis@ico.unicancer.fr",[42,61,75,88,101,116,127,138],{"facility":43,"status":44,"city":45,"state":21,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"ICO - Site Paul Papin","RECRUITING","Angers","49055","France","FR",{"type":50,"coordinates":51},"Point",[52,53],-0.55202,47.47156,{"lat":53,"lon":52},[56,59],{"name":57,"role":33,"phone":21,"phoneExt":21,"email":58},"Augustin P REYNARD, MD","augustin.reynard@ico.unicancer.fr",{"name":60,"role":30,"phone":21,"phoneExt":21,"email":21},"Sandrine HIRET, MD",{"facility":62,"status":44,"city":63,"state":21,"zip":64,"country":47,"countryCode":48,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Institut Bergonie","Bordeaux","33076",{"type":50,"coordinates":66},[67,68],-0.58046,44.84124,{"lat":68,"lon":67},[71,74],{"name":72,"role":33,"phone":21,"phoneExt":21,"email":73},"Sophie AURIOL-LEIZAGOYEN, MD","s.auriol@bordeaux.unicancer.fr",{"name":72,"role":30,"phone":21,"phoneExt":21,"email":21},{"facility":76,"status":44,"city":77,"state":21,"zip":78,"country":47,"countryCode":48,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Institut de cancérologie de Montpellier","Montpellier","34298",{"type":50,"coordinates":80},[81,82],3.87635,43.61093,{"lat":82,"lon":81},[85],{"name":86,"role":33,"phone":21,"phoneExt":21,"email":87},"Marian GUTOWSKI, MD","marian.gutowski@icm.unicancer.fr",{"facility":89,"status":44,"city":90,"state":21,"zip":91,"country":47,"countryCode":48,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Centre Antoine Lacassagne","Nice","06189",{"type":50,"coordinates":93},[94,95],7.26608,43.70313,{"lat":95,"lon":94},[98],{"name":99,"role":33,"phone":21,"phoneExt":21,"email":100},"Marie GOSSET, MD","marie.gosset@nice.unicancer.fr",{"facility":102,"status":103,"city":104,"state":21,"zip":105,"country":47,"countryCode":48,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Institut Curie - Site de Paris","NOT_YET_RECRUITING","Paris","75005",{"type":50,"coordinates":107},[108,109],2.3488,48.85341,{"lat":109,"lon":108},[112,115],{"name":113,"role":33,"phone":21,"phoneExt":21,"email":114},"Enora LAAS, MD","enora.laas@curie.fr",{"name":113,"role":30,"phone":21,"phoneExt":21,"email":21},{"facility":117,"status":44,"city":104,"state":21,"zip":118,"country":47,"countryCode":48,"cosmosGeoPoint":119,"geoPoint":121,"contacts":122},"Hopital Saint Joseph","75014",{"type":50,"coordinates":120},[108,109],{"lat":109,"lon":108},[123,126],{"name":124,"role":33,"phone":21,"phoneExt":21,"email":125},"Séverine ALRAN, MD","Salran@hpsj.fr",{"name":124,"role":30,"phone":21,"phoneExt":21,"email":21},{"facility":29,"status":44,"city":128,"state":21,"zip":129,"country":47,"countryCode":48,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Saint-Herblain","44805",{"type":50,"coordinates":131},[132,133],-1.651,47.21154,{"lat":133,"lon":132},[136,137],{"name":28,"role":33,"phone":21,"phoneExt":21,"email":36},{"name":28,"role":30,"phone":21,"phoneExt":21,"email":21},{"facility":139,"status":44,"city":140,"state":21,"zip":141,"country":47,"countryCode":48,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"IUCT-O","Toulouse","31059",{"type":50,"coordinates":143},[144,145],1.44367,43.60426,{"lat":145,"lon":144},[148,151],{"name":149,"role":33,"phone":21,"phoneExt":21,"email":150},"Gabrielle SELMES, MD","selmes.gabrielle@iuct-oncopole.fr",{"name":152,"role":30,"phone":21,"phoneExt":21,"email":21},"Gabrielle SELMES",{"type":154,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100413697","phase-2-impact-of-neoadjuvant-hormonal-therapy-on-the-surgical-management-of-extensive-ductal-carcinomas-in-situ-100413697",false,"NCT04666961","Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ","HORNEO01","Inclusion Criteria:\n\n1. Patient ≥ 40 years old\n2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent\n3. Clinical T0N0\n4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status\n5. Indication for mastectomy\n6. DCIS visible on MRI performed with clip sequence\n7. Effective contraceptive method for women of childbearing age who are sexually active and who have reported sexual activity.\n8. Informing the patient and obtaining free, informed and written consent signed by the patient and the investigator.\n9. Affiliated patient or beneficiary of the social security system.\n\nExclusion Criteria:\n\n1. Invasive breast carcinoma\n2. Lobular carcinoma in situ\n3. pN+ patient\n4. Indication for conservative surgery\n5. Contraindications to anastrozole or tamoxifen\n6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by interaction with cytochrome CYP2D6.\n7. Histologically proven multifocal lesion\n8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal or peripheral stimulator, severe claustrophobia, ...)\n9. History of homolateral breast cancer\n10. Ongoing contralateral breast cancer\n11. Known mutation BRCA1 BRCA2\n12. Other cancer in progress at inclusion\n13. Pregnant woman, or breastfeeding,\n14. Persons deprived of liberty or under guardianship or trusteeship,\n15. Impossibility to undergo the medical follow-up of the trial for geographical, social, psychic or psychiatric reasons.","FEMALE","40 Years",{"count":165,"type":166},262,"ESTIMATED","INTERVENTIONAL",[169],"PHASE2","Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications.\n\nThis mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients.\n\nNeoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy.\n\nAdjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence.\n\nThe HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.",[172,173,174],"Ductal Carcinoma in Situ","Extensive Disease","Mastectomy",[176,177,178,179,180,181],"Neoadjuvant hormonotherapy","Tamoxifen","Anastrozole","conservative surgery","Breast cancer","extensive microcalcifications","2022-04-21",{"date":184,"type":185},"2022-04-22","ACTUAL",{"date":187,"type":185},"2021-02-03",{"date":189,"type":166},"2033-08-01",{"name":5,"class":6},8]